BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17218850)

  • 1. Positron emission tomography imaging for gynecologic malignancy.
    Lai CH; Yen TC; Chang TC
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):37-41. PubMed ID: 17218850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography in gynecologic cancer.
    Yen TC; Lai CH
    Semin Nucl Med; 2006 Jan; 36(1):93-104. PubMed ID: 16356798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography in gynecological malignancies.
    Kumar R; Chauhan A; Jana S; Dadparvar S
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1033-44. PubMed ID: 16831075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of FDG-PET in cervical cancer and endometrial cancer: utility and future prospects.
    Nogami Y; Iida M; Banno K; Kisu I; Adachi M; Nakamura K; Umene K; Masuda K; Tominaga E; Tanaka K; Aoki D
    Anticancer Res; 2014 Feb; 34(2):585-92. PubMed ID: 24510987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of PET Imaging in Gynecologic Radiation Oncology.
    Rao YJ; Grigsby PW
    PET Clin; 2018 Apr; 13(2):225-237. PubMed ID: 29482751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET for management of cervical and ovarian cancer.
    Havrilesky LJ; Kulasingam SL; Matchar DB; Myers ER
    Gynecol Oncol; 2005 Apr; 97(1):183-91. PubMed ID: 15790456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET Assessment of Other Gynecologic Cancers.
    Faria S; Devine C; Viswanathan C; Javadi S; Korivi BR; Bhosale PR
    PET Clin; 2018 Apr; 13(2):203-223. PubMed ID: 29482750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of
    Narayanan P; Sahdev A
    Br J Radiol; 2017 Nov; 90(1079):20170283. PubMed ID: 28830238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic monitoring of advanced uterine cervical cancer neoadjuvant chemotherapy by using [F-18]-Fluorodeoxyglucose positron emission tomography: preliminary results in three patients.
    Yoshida Y; Kurokawa T; Kawahara K; Yagihara A; Tsuchida T; Okazawa H; Fujibayashi Y; Yonekura Y; Kotsuji F
    Gynecol Oncol; 2004 Dec; 95(3):597-602. PubMed ID: 15581970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT.
    Lerman H; Metser U; Grisaru D; Fishman A; Lievshitz G; Even-Sapir E
    J Nucl Med; 2004 Feb; 45(2):266-71. PubMed ID: 14960646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gynecological cancers.
    Avril N; Gourtsoyianni S; Reznek R
    Methods Mol Biol; 2011; 727():171-89. PubMed ID: 21331934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer.
    Yen TC; Ng KK; Ma SY; Chou HH; Tsai CS; Hsueh S; Chang TC; Hong JH; See LC; Lin WJ; Chen JT; Huang KG; Lui KW; Lai CH
    J Clin Oncol; 2003 Oct; 21(19):3651-8. PubMed ID: 14512397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area.
    Boughanim M; Leboulleux S; Rey A; Pham CT; Zafrani Y; Duvillard P; Lumbroso J; Haie-Meder C; Schlumberger M; Morice P
    J Clin Oncol; 2008 May; 26(15):2558-61. PubMed ID: 18487573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers.
    Zukotynski KA; Kim CK
    PET Clin; 2017 Oct; 12(4):393-405. PubMed ID: 28867111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludeoxyglucose F 18 PET-Computed Tomography: Management Changes Effecting Patient Outcomes in Gynecologic Malignancies.
    Brunetti JC
    PET Clin; 2015 Jul; 10(3):395-409. PubMed ID: 26099674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.
    Lai CH; Huang KG; See LC; Yen TC; Tsai CS; Chang TC; Chou HH; Ng KK; Hsueh S; Hong JH
    Cancer; 2004 Feb; 100(3):544-52. PubMed ID: 14745871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metabolic imaging with positron-emission tomography in the advanced-stage ovarian cancers].
    Grahek D; Hassan-Sebbag N
    Bull Cancer; 2009 Dec; 96(12):1163-71. PubMed ID: 19948451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
    Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
    Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.